SF126
1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
SF-126 cells are a patient-derived glioblastoma cell line that originates from a frontal lobe tumor. These cells lack the expression of glial markers GFAP or glutamine synthetase but show positive expression for laminin and fibronectin in early passages, 
indicating they may be proliferative or transformed mesenchymal cells of glioblastoma. In culture, SF-126 cells exhibit hypertriploidy and have a fibroblastic morphology. They are non-tumorigenic in athymic mice and have the ability to form collagen fibers in vitro. The cells were also confirmed through immunostains for procollagen III, further characterizing their mesenchymal nature.
Why choose SF126 from AcceGen?
SF126 cells are provided in each vial at a amount of more than 1×106 viable cells. They are confirmed to be of human origin and are free from interspecies contamination with mouse, rat, Chinese hamster, Golden Syrian hamster, and non-human primate (NHP). Additionally, the cells are tested and found negative for infectious diseases and mycoplasma contamination. The unique identity of each cell line is further verified through STR analysis during genotyping.
| Product Code | SF-126; SF 126 |
| Species | Human |
| Cat.No | ABC-TC1017 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Fibroblast-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Brain |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Nerve Tumors Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
SF126 cells serve as a valuable tool for studying the cell biology of gliomas and are established as a model for human glioblastoma. Their significance lies in their ability to provide insights into various aspects of cellular physiology and chemosensitivity related to gliomas. They offer a platform to evaluate potential therapies, including radiation, for human gliomas, aiding in the development and testing of novel treatment strategies for this aggressive form of brain cancer.
